DNV 3837
Alternative Names: DNV 3681; DNV-3837; MCB-3681; MCB-3837; OxaquinLatest Information Update: 16 Oct 2025
At a glance
- Originator Morphochem AG
- Developer Biovertis AG; Deinove; Evotec SE; United States Army Medical Research Institute of Infectious Diseases
- Class Acetamides; Antibacterials; Carboxylic acids; Cyclopropanes; Fluorobenzenes; Oxazolidinones; Phenyl ethers; Phosphates; Piperidines; Quinolines; Quinolones; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors; Enzyme inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Clostridium difficile infections
- Discontinued Anthrax; Bacterial infections; Nosocomial infections; Tularaemia
Most Recent Events
- 16 Oct 2025 Discontinued - Phase-I for Bacterial infections in Germany (IV)
- 16 Oct 2025 Discontinued - Phase-II for Clostridium difficile infections in USA (IV)
- 16 Oct 2025 Discontinued - Preclinical for Anthrax in USA (IV)